There are many options available allowing patients with diabetes to monitor and manage their glucose levels. The continuous glucose monitor (CGM) shown here includes a glucose level sensor and transmitter, a data receiver which displays the patient’s glucose levels, and an insulin delivery system.
Diabetes is caused by defects in the body’s ability to produce or use insulin—a hormone that controls blood sugar levels and helps convert food into energy. If the pancreas doesn’t make enough insulin, or if the insulin that is produced does not function properly, a person’s blood sugar level becomes too high. Over time, that can lead to serious health problems, including:
Low blood sugar can also be dangerous, causing you to feel shaky or pass out.
If you have diabetes, there are several types of devices that can help you keep your blood sugar level within safe ranges. Here are three options you and your healthcare provider may want to consider:
There are currently two FDA-approved, CGM-enabled insulin pumps: the Medtronic MiniMed, approved in April 2006, and the Animas Vibe System, which was approved on Nov. 25, 2014. The Animas Vibe System combines the DexCom G4 Platinum CGM with an Animas insulin pump. This approval gives consumers more choices in the types of CGMs that can be integrated wirelessly with an insulin pump.
“These devices are an important technological advance to address some of the challenges people with diabetes face in managing their blood sugar,” says Alberto Gutierrez, Ph.D., director of FDA’s Office of In Vitro Diagnostics and Radiological Health. “As they become better integrated with insulin pumps, CGMs can ease the daily burden of people with diabetes who juggle the use of multiple medical devices.”
In addition, researchers are making significant progress towards the development of artificial pancreas device systems (APDS). These automated, closed-loop systems combine a continuous glucose monitor, an insulin infusion pump, and a “smart” system that monitors glucose levels in the body and automatically pumps appropriate doses of insulin when needed, with little or no input from the patient. The ideal APDS will be a system of devices that closely mimics the glucose-regulating function of a healthy pancreas. It will not only monitor glucose levels but also automatically adjust the delivery of insulin to reduce high blood glucose levels (hyperglycemia) and minimize the incidence of low blood glucose (hypoglycemia).
Currently many investigational studies involved in the development of APDS are using sensor enabled pumps, including ones that integrate the G4 Platinum System, as a component. The availability of an insulin pump that is already compatible with the G4 Platinum system will make the development and approval of APDS that use this technology easier. The FDA will continue to prioritize the development of an APDS and will continue to keep you and health care professionals informed of developments.
.